GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Gross-Profit-to-Asset %

Pharming Group (XAMS:PHARM) Gross-Profit-to-Asset % : 41.82% (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Pharming Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharming Group's annualized Gross Profit for the quarter that ended in Mar. 2024 was €173.7 Mil. Pharming Group's average Total Assets over the quarter that ended in Mar. 2024 was €415.4 Mil. Therefore, Pharming Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 41.82%.


Pharming Group Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharming Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Gross-Profit-to-Asset % Chart

Pharming Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.78 54.00 45.22 47.12 48.85

Pharming Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.06 45.86 54.30 65.23 41.82

Competitive Comparison of Pharming Group's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharming Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharming Group's Gross-Profit-to-Asset % falls into.



Pharming Group Gross-Profit-to-Asset % Calculation

Pharming Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=201.835/( (401.952+424.437)/ 2 )
=201.835/413.1945
=48.85 %

Pharming Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=173.696/( (424.437+406.335)/ 2 )
=173.696/415.386
=41.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Pharming Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharming Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group (XAMS:PHARM) Business Description

Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.

Pharming Group (XAMS:PHARM) Headlines

No Headlines